Las Vegas, NV, November 27, 2007 --(PR.com
)-- Laurent Lecanu, Ph.D., Pharm.D., will present data for Samaritan's promising Alzheimer's drug Caprospinol (SP-233) at the Alzheimer's Drug Development Summit in Arlington, VA on Friday, November 30th at 9:45a.m./ET. Dr. Lecanu will present Caprospinol as the first drug to demonstrate in animals that there is a correlation between clearing beta-amyloid from the brain and the recovery of memory function. Dr. Lecanu's presentation is entitled "Caprospinol Improves Brain Histopathology and Recovers Memory Function in a Rat Model of Alzheimer's Disease.''
In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with the disease. The rats tested with the company's proprietary Alzheimer's rat model took on features similar to the crippling signs of dementia seen in human patients suffering from Alzheimer's; by treating the rats with Caprospinol, the rat's brain cells regained complete memory.
Dr. Lecanu is an associate professor of the Department of Medicine at the Research Institute of the McGill University Health Centre and through a Samaritan research collaboration with McGill University heads Samaritan's research efforts.
Samaritan Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company that concentrates its efforts toward commercializing new innovative therapeutic products. Samaritan has partnered its Phase II infectious disease drug SP-01A, an oral HIV viral-entry inhibitor, to Pharmaplaz, Ireland. Additionally, its Alzheimer's drug Caprospinol, with the potential to restore memory loss in Alzheimer's disease patients, has been issued an IND by the FDA. Samaritan has several drugs in nonclinical studies preparing for IND development; it is evaluating the use of SP-1000 for hypercholesterolemia patients and the use of SP-10T1 as an ``oral treatment'' for Hepatitis-C. In addition, Samaritan has acquired the marketing and sales rights to sell eleven revenue-generating products in various Eastern European countries.
Please register so we can notify you of upcoming conference calls, news and events.
The Investor Relations Group
Samaritan Pharmaceuticals, Inc.